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Abstract
Background: No data were available on the epidemiolog-
ical and clinical characteristics of bacillary angiomatosis
(BA) in Germany. Objective: To determine epidemiologi-
cal and clinical data on HIV-associated BA. Methods: A
chart review of all BA cases between 1990 and 1998 was
performed in 23 German AIDS treatment units. Results:
A total of 21 cases of BA was diagnosed. During this peri-
od, the participating HIV centers treated about 17,000
HIV-infected patients. As a result, a BA prevalence of 1.2
cases/1,000 patients can be assumed. 19 BA were local-
ized in the skin; in 5 cases bones and in 4 cases the liver
were involved. Out of 20 patients who received antibiotic
therapy, 13 had complete remission. The median time of
duration up to complete remission was 32 days (9–82).
During the follow-up of the 20 patients, 7 relapses were
observed. Conclusion: BA is a rare HIV-associated dis-
ease with a prevalence of 1,2 cases/1,000 patients in the
presented study.
Copyright © 2000 S. Karger AG, Basel
Introduction
Bacillary angiomatosis (BA), also termed epithelioid
angiomatosis, is an angioproliferative disease first de-
scribed in 1983 by Stoler et al. [1]. It has occurred most
commonly in patients with severe immunosuppression
caused by the human immunodeficiency virus (HIV). BA
has only rarely been discovered in patients with other
kinds of immunosuppression, such as organ transplant
recipients or immunocompromised individuals [2, 3].
The disease derived its name from the vascular prolifera-
tion seen in histological tissue examination and from the
presence of numerous bacillary organisms detectable in
Warthin-Starry silver staining or electron microscopy [4]
(fig. 1c). In recent years, molecular biological techniques,
which allow for an exact pathogen typing, have become
established [5] (fig. 1d).
The first described clinical manifestation of an infec-
tion with organisms of the Rochalimaea genus (now
known as Bartonella) was called ‘trench fever’ as it
appeared among the battlefield troops in World War I [6].
In 1990, Relman et al. [7] recognized a relationship
between the ‘trench fever’ microorganism and the bacteri-
um Rochalimaea quintana (now Bartonella quintana), the
agent of BA. In 1992, another member of the genus Bar-
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Fig. 1. 53-year-old HIV-infected patient with BA manifestations of the skin, liver, bones and pancreas as well as
pronounced general symptoms and a weight loss of 15 kg. The patient was treated with 2 g/day of erythromycin per os
for 12 weeks. This therapy led to a complete remission of all lesions and an increase in weight by 18 kg. Until the time
of evaluation (12 months after the end of the therapy), the patient had no relapse of BA. a A 3 ! 5 cm ulcerated
nodule on the patient’s shoulder which, later, was completely excised surgically. b The lytic bone lesion of a thoracic
vertebra. c The tissue from a under an electron microscope. Multiple bacteria can be seen with the form and
wall structure characteristic of the Bartonella group pathogen. d The polymerase chain reaction in the focus from a.
Lane 1: DNA molecular size markers; lane 2: negative control; lane 3; positive control; lane 4: EDTA blood of the
described patient; lane 5: tissue of the lesion shown in a.
tonella, B. henselae, was also recognized to be associated
with this illness [8]. BA typically presents itself as an
inflammatory disease, most often involving the skin. Cu-
taneous lesions may be solitary or multiple and can be
localized superficially, in the skin or subcutaneously
(fig. 1a). In addition, oral, anal, conjunctival and gastroin-
testinal mucosal surfaces, as well as the liver, bones,
lymph nodes, spleen and several other organs may be
involved (fig. 1b). These lesions grow slowly over a period
of several weeks. In patients afflicted with this disorder,
other symptoms like fever, loss of weight or an overall
feeling of illness typically appear. On histological exami-
nation, lesions of BA consist of lobular proliferations of
small blood vessels containing plump, cuboidal endothe-
lial cells. These are interspersed with mixed inflammatory
cell infiltrates having a predominance of neutrophils [9].
Because of the infrequent occurrence of BA, there is no
uniform scheme of therapy, but, in patients with HIV
infections, experienced clinicians recommend antibiotic
treatment with oral erythromycin or doxycycline over a
period of 8–12 weeks [10].
In 1993, the first cases of BA were described in Germa-
ny [11, 12]. Although a few cases were reported during the
following years [13], no synopsis of the different BA infec-
tions in Germany was carried out.
Consequently, we conducted a retrospective investiga-
tion with various centers of the German AIDS Study
Group to obtain epidemiological and clinical data on
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HIV-associated BA in Germany. To our knowledge, this
study describes the largest published series of HIV-
infected patients with BA in a clearly characterized region
of Europe.
Methods
We conducted a retrospective multicenter study in Germany in
order to analyze epidemiological and clinical data of patients with
HIV-associated BA. 23 German HIV centers (see appendix) associat-
ed with the German AIDS Study Group (GASG/IdkF) participated
in this evaluation. Standardized data on the medical histories of all
HIV-infected patients with BA were gathered in the period form Jan-
uary 1, 1990, to December 31, 1998. To verify the diagnosis of BA
there had to be typical clinical manifestations in combination with
histological findings of respective bacteria in Warthin-Starry staining
or electron microscopy or identification of the Bartonella species by
molecular biological techniques. General demographic data were
analyzed as well as details of clinical manifestation and diagnosis of
BA, treatment and clinical outcome. This study was conducted with
the support of the AIDS-Center of the Robert Koch Institute/Bun-
desministerium für Gesundheit file 415-4476-09/25.
Results
Between 1990 and 1998, 23 HIV centers associated
with the GASG/IdkF treated a total of 17,626 HIV-
infected patients. During this period, 21 cases of BA were
documented. The prevalence of BA was therefore 11.9
cases/10,000 HIV-infected patients. Of these 21 patients,
19 were male and 2 female. The median age was 39 years
(26–71 years). Nineteen patients (90%) had CD4-positive
lymphocytes less than 100 cells/Ìl, but 2 had distinctly
more than 300 cells/Ìl (350, 405 cells/Ìl). The median
CD4 cell count was 30 cells/Ìl (0–405 cells/Ìl). According
to the classification of the Centers for Disease Control, in
13 of the 21 individuals the stage of the HIV infection was
C (AIDS), in 6 patients B3 and in 2 B2. Nine patients had
been afflicted with Kaposi’s sarcoma in their medical his-
tory, 6 with Pneumocystis carinii pneumonia and 4 pa-
tients with cytomegalovirus infections; in 4 cases, esopha-
geal candidiasis had been diagnosed and 2 patients had
cerebral toxoplasmosis.
In 18 cases, the diagnosis of BA was verified by War-
thin-Starry staining, in 4 patients electron microscopy
was performed and in 3 patients molecular biological
methods were applied.
In 19 out of the 21 patients with BA the skin was
involved, in 5 cases the bones were infected and 4 patients
had manifestations in the liver. Three of the individuals
had BA of the lymph nodes. In 2 patients, the mucous
membranes were involved. One patient had a manifesta-
tion of the spleen and another of the central nervous sys-
tem (table 1).
In the cases of cutaneous BA, the median number of
lesions was 9 (1–80). In 12 cases, they were localized at the
lower extremities, in 11 patients at the upper extremities,
8 patients had manifestations of the trunk, another 8 on
the head and 2 patients had mucocutaneous manifesta-
tions of the oral cavity.
All 19 patients with cutaneous manifestations had der-
mal papules or nodules; 8 cases showed additionally ulcer-
ation and crusting. In 4 patients, plaques were described.
Systemic symptoms were documented in 11 patients: the
symptoms involved fever in 9 patients, weight loss in 3
and nighttime sweating in 4 cases. Only 11 patients were
found to have had contact with cats. In 10 cases, no con-
tact with cats was documented. One patient owned a cat
but denied being scratched. Out of 21 patiens with BA, 20
received antibiotic therapy. In 15 patients, erythromycin
was used; 2 patients received doxycyline, while 3 other
patients were each treated with amoxillin/clavulanic acid,
cefuroxime and imipenem. Thirteen patients had a com-
plete remission, while in 7 patients only a partial response
was observed. The median duration of treatment was 28
days (5–240 days). The median time needed to achieve a
complete response was 36 days (19–240 days). However,
3 patients with a complete response and 4 patients with a
partial response had a relapse after antibiotic therapy.
Four of the 7 patients with relapses were treated with
erythromycin; each was treated with imipenem, amoxicil-
lin and cefuroxime. The antibiotic therapy of the 7
patients lasted a median of 21 days (13–88 days). After
completion of the antibiotic therapy, the median time of
relapse was 5 weeks (3–16 weeks).
Up to the time of evaluation, 7 patients had died
(fig. 2). The median duration between time of diagnosis of
BA and death was 8 months (0–34 months). One of these
patients died from peliosis hepatis with dissemination to
multiple organs including the lungs and the bones before
therapy could be initiated. Although the patient did not
present any skin lesions that could have suggested BA, the
infection was diagnosed on autopsy. In the other deceased
patients, the shortest time between diagnosis of BA and
death was 2 months. In none of these 6 cases was BA the
cause of death. All patients died from other complications
of their HIV infection.
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Fig. 2. Kaplan-Meyer analysis of the surviv-
al of the 21 described patients with BA.
Table 1. Demographic and clinical data of 21 patients with BA
Patient
No.
Age
years
Sex CDC
stage
CD4 cells
!106/l
Involved organs Diagnostics Antibiotic therapy Outcome
28 M C3 31 Skin, lymph node HE Erythromycin,
6 weeks
CR, no relapse
2 40 M C3 20 Liver, bone,
lymph node
WS, HE No therapy Died before therapy
could be initiated
3 53 M C3 57 Skin WS, HE Erythromycin,
8 weeks
CR, no relapse
4 35 M B3 34 Skin WS, HE, EM, PCR Erythromycin,
13 weeks
CR, no relapse
5 35 M C3 10 Skin, bone HE, PCR Erythromycin,
4 weeks
PR, no relapse
6 56 M C2 406 Skin WS, HE, EM Erythromycin,
5 weeks
CR, no relapse
7 28 M C3 15 Skin WS, HE Erythromycin,
5 weeks
CR, no relapse
8 49 M C3 20 Skin, CNS WS, HE, EM Erythromycin,
19 days
CR, relapse after
5 weeks
9 45 M C3 13 Skin, bone WS, HE Erythromycin,
6 weeks
CR, relapse 6 weeks
after end of therapy
10 32 M B3 10 Skin WS, HE Cefuroxime,
3 weeks
PR, relapse 6 weeks
after end of therapy
11 29 M C3 14 Skin, lymph node WS, HE, EM Doxycycline,
34 weeks
CR, no relapse
12 41 M B3 60 Skin WS Erythromycin,
3 weeks
CR, relapse 3 weeks
after end of therapy
13 73 W B3 70 Skin WS Erythromycin,
3 weeks
CR, no relapse
14 52 M C3 70 Skin WS, HE Erythromycin,
3 weeks
CR, no relapse
15 39 M C3 30 Skin WS, HE Amoxicillin,
3 weeks
PR, relapse 3 weeks
after end of therapy
16 28 W B2 34 Skin, liver WS, HE, PCR Erythromycin,
3 weeks
CR, no relapse
17 40 M B3 10 Skin, liver,
mucous membrane
WS, HE Erythromycin,
12 weeks
PR, relapse after
16 weeks
18 31 M C3 20 Skin, bone WS, HE Imipenem,
13 days
PR, relapse 8 weeks
after end of therapy
19 28 M B3 49 Skin WS, HE Erythromycin,
3 weeks
PR, no relapse
20 33 M B2 350 Mucous membrane WS, HE Doxycycline,
5 days
PR, no relapse
21 35 M C3 37 Skin, liver, spleen,
bone
WS, HE Erythromycin,
7 weeks
CR, no relapse
WS = Warthin-Starry staining; HE = hematoxylin-eosin staining; EM = electron microscopy; PCR = polymerase chain reaction;
M = man; W = woman; PR = partial remission; CR = complete remission.
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Discussion
Despite the common occurrence of Bartonella infec-
tions with more than 40,000 cases of cat scratch disease
each year in the USA, BA remains a rare disorder. The
prevalence of BA in the presented study was 1.2 cases/
1,000 HIV-infected patients. LeBoit [4] estimated 1 case
of BA for every 25–50 afflictions with Kaposi’s sarcoma.
Under the assumption that Kaposi’s sarcoma makes up
about 20% of the manifestations in patients with AIDS, in
our study population LeBoit’s estimation would forecast
125–250 AIDS patients with BA. Considering the fact
that the number of HIV-infected patients is about three
times higher than of those with AIDS, LeBoit’s estima-
tions correspond quite well with our results. Nevertheless,
presumably even today not all cases of BA are diagnosed
and the implementation of antibiotic prophylactics (e.g.
with cotrimoxazole or clarithromycin) considerably af-
fects the incidence of BA. In accordance with Cockerell,
we observed that most of the affected patients (90%) had
a severe immunosuppression with less than 100/Ìl CD4
cells [14]; however, 2 of the 21 patients had significantly
more than 200/Ìl CD4 lymphocytes.
A frequently recurring topic in the medical literature
on BA is the question of pathogen transmission via cats.
Tappero et al. [15] were able to show an association
between the appearance of BA and previous scratching by
cats. For various Bartonella infections, arthropods were
able to be identified as vectors: B. bacilliformis is trans-
mitted by sand flies, B. quintana by body lice and B. hen-
selae by cat fleas [5, 16]. Correspondingly, Koehler et al.
[5, 17] and Gasquet et al. [18] discovered an association
betwen B. quintana infections and homelessness or low
social standard as well as between B. henselae infections
and contact with cats. Even today, it is still not clear
whether B. henselae is transmitted to humans via direct
contact with cats or via the vector of the cat flea. In our
study, previous traumatic or atraumatic contact with cats
could only be verified for 11 of the 21 patients. Ten
patients had no previous contact with cats while the only
patient who owned a cat denied having any traumatic
contact with the pet.
As many authors have already pointed out, our find-
ings verified the skin as the most frequently affected organ
[19, 20]. In our study, 90% of the patients had lesions of
the skin and 24% of the bones. Cockerell [14] states that
infection of the bones occurs in 35% of the cases.
Although antibiotic therapies had been initiated in all
premortally diagnosed cases, the rate of complete remis-
sion in the described patients was only 70%. The reasons
for this poor outcome is probably the comparatively short
duration of therapy, with an average of 35 days. The cur-
rent medical literature recommends a treatment of 8–16
weeks [10]. This may also be the explanation for the high
rate of relapses (28%).
The work presented here was largely based on the diag-
nosis of BA by Warthin-Starry staining in combination
with clinical findings. Molecular biological techniques,
like PCR, which is today commonly used for verification
and identification of pathogens, were for the most part
not yet available at the time of the described BA cases [5].
Nevertheless, a high level of clinical suspicion remains the
most important first step to the diagnosis of BA in HIV-
infected patients.
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Appendix
Participating centers of the German AIDS Study Group (GASG/
IdkF): (1) Bernhard-Nocht-Institut für Tropenmedizin, Hamburg;
(2) Medizinische Poliklinik am Universitätskrankenhaus Eppendorf,
Hamburg; (3) Allgemeines Krankenhaus St. Georg, Hamburg;
(4) Auguste-Viktoria-Krankenhaus, Berlin; (5) Klinik Steglitz der
Benjamin-Franklin-Universität Berlin; (6) Krankenhaus Prenzlauer
Berg, Berlin; (7) Abteilung Immunologie der Medizinischen Hoch-
schule Hannover; (8) Zentrum für Innere Medizin, Göttingen;
(9) Medizinische Klinik der Universität Düsseldorf; (10) Dermatolo-
gische Klinik der Universität Essen; (11) Klinik und Poliklinik für
Dermatologie der Universität Köln; (12) Medizinische Universi-
tätsklinik Bonn; (13) Zentrum für Dermatologie und Venerologie,
Universität Frankfurt; (14) Zentrum für Innere Medizin der Univer-
sität Frankfurt; (15) Medizinische Klinik und Poliklinik der Johann-
Gutenberg-Universität Mainz; (16) Medizinische Klinik und Poli-
klinik der Universität Saarland; (17) Universitätshautklinik Heidel-
berg; (18) Krankenhaus Schwabing, München; (21) Dermatologische
Klinik und Poliklinik der Universität München; (22) Medizinische
Poliklinik der Universität München; (23) Medizinische Klinik und
Poliklinik der Universität Köln.
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